Life Science Risk Assessment
Comprehensive risk assessment across clinical, regulatory, commercial, and technical dimensions. Physician-engineer analysis backed by proprietary data. Results in as fast as 24 hours.
The Process
Three steps from submission to actionable intelligence
Complete a brief intake form about your device, regulatory status, and strategic goals. Takes about 10 minutes. We handle the rest.
Our physician and biomedical engineer conduct independent reviews drawing on federal regulatory data and clinical-technical expertise. Co-review ensures rigorous, multi-disciplinary assessment.
A clear, concise report covering risk classification, strategic positioning, and prioritized next steps — calibrated to your role (founder, investor, acquirer, or TTO).
Your Deliverable
A clear, actionable report calibrated to your role and decision stage
Based on comprehensive multi-category analysis across multiple proprietary assessment domains
A composite Vantage Index with risk classification, contextualized against comparable medical devices with evidence-grounded methodology.
Analysis across clinical, regulatory, commercial, and technical dimensions — each grounded in verifiable federal data sources.
Your strongest competitive positions and the risk areas requiring attention — prioritized by impact and urgency for your specific situation.
Actionable recommendations tailored to your role — whether you're building, investing, acquiring, or licensing.
Our Approach
Not just data. Physician judgment applied to every assessment.
Every assessment is reviewed by Arvind Ravinutala, MD with clinical context that pure data platforms miss — regulatory nuance, adoption barriers, and reimbursement realities.
Aswini Ravinutala, BME brings device design, manufacturing quality systems, and technical feasibility analysis to every assessment.
Assessments are grounded in proprietary regulatory data, fully cited in your report with verifiable sources.
A founder gets different recommendations than an investor or acquirer. Your report speaks your language and addresses your specific decision criteria.
How It Works
Illustrative scenarios showing how the Vantage Index informs critical decisions
A VC fund needed rapid assessment of a Phase 2 oral GLP-1 compound. Vantage identified a manufacturing scalability gap in peptide synthesis and a competitive window risk from 3 late-stage competitors. The assessment flagged the compound's differentiated bioavailability profile as a key strength.
How it helps: The fund can price the round against a risk-adjusted view of the manufacturing and clinical gaps.
An early-stage diagnostics company needed investor-readiness assessment before Series A. Vantage identified that the CLIA waiver pathway was feasible but reimbursement coding would require a new CPT application. The assessment highlighted strong clinical evidence from 3 peer-reviewed studies.
How it helps: The founder can enter the raise with the reimbursement gap quantified and a remediation path attached to the data room.
A large device company evaluating an acquisition target in digital health. Vantage identified cybersecurity gaps in the De Novo submission strategy and flagged interoperability risks with legacy EHR systems. The assessment confirmed strong real-world evidence from 15,000-patient registry.
How it helps: The acquirer can weigh the cybersecurity remediation cost before finalizing the offer.
Risk Assessment
Understand the hidden risk exposure in your deal and see how Vantage helps you move faster with confidence.
Pricing
The diligence a physician and biomedical engineer would run on a deal — every claim cited to a public source, in hours, at a fraction of your alternative.
Annual License · Flagship
License Vantage — your fund's diligence bench, on tap: unlimited screening plus diligence reports every year, priced to how many deals you run. A fraction of the $150–250K associate you can't hire.
Scout
Fund
Platform
Eight Diligence Reports bought individually would run $120,000 (8 × $15,000) — the Fund license is $75,000 and includes unlimited triage and portfolio monitoring; additional reports beyond your tier are $12,000 each.
Enterprise — for high-volume funds & PE portfolios: unlimited Diligence Reports, full portfolio monitoring, and post-close tracking, from $150,000/yr, scoped to your portfolio. See portfolio & PE →
À La Carte
See the exact work on a real deal before you commit — a full, cited read you can check yourself.
Commissioning a single evaluation? Its fee credits in full toward a Vantage License.
Evaluating an acquisition? See the M&A Report ($25,000) →
Universities, accelerators & incubators: Vantage embeds into your program → for TTOs · for accelerators
Every material claim is cited to a public source — we never fabricate. Each engagement is authored through a dual lens: Arvind Ravinutala, MD (physician executive) on clinical & regulatory, and Aswini Ravinutala, BME (biomedical engineer) on technical, IP & manufacturing.
Example
A realistic sample from a de-identified medical device company
Your automated Quick Screen brief (markdown, ~2 pages) includes:
Section 1: Composite Score & Risk Classification
proprietary multi-factor risk assessment, RED/YELLOW/GREEN risk flag, confidence bands per category
Section 2: Data Audit Trail & Summary
Data completeness per category, federal database citations, automated scoring methodology
Why Trust Vantage
Covering medical devices, pharmaceuticals, biologics, diagnostics, digital health, therapeutics, and combination products
Clinical perspective from Arvind Ravinutala, MD. Real-world understanding of regulatory workflows, clinical adoption barriers, and investor expectations.
Technical rigor from Aswini Ravinutala, BME. Deep expertise in device design, manufacturing quality systems, and product-market complexity.
Federal databases, regulatory records, clinical evidence, and market intelligence — cross-referenced and cited in every report you receive.
Questions about how we protect your data?
Data Security & Privacy → • Book a 20-Min Discovery Call →Get your Vantage Index in as little as 24 hours. No weeks of waiting. Just clear data, expert analysis, and actionable insights.
Or email arvind@vantagebiomed.com directly